• Subretinal fibrosis (SRF) is defined as the development of disciform scar and fibrosis underneath the retina which can cause vision loss through macular edema and detachment

• The irreversible fibrosis development is closely associated with most of the major ocular diseases such as wet AMD, diabetic retinopathy (DR), central retinal vein occlusion (CRVO), and so on, but there is no FDA-approved treatment for this condition

• Development under consultation with a science advisory board member, Prof. Demetrios Vavvas at Harvard Medical School

• The potential of a first-in-class therapeutic to treat SRF and CNV (Choroidal Neovascularization) in wet AMD patients

• Promising efficacies in animal models for SRF and CNV are confirmed (ongoing)

• Expanded License and Collaboration Agreement with Théa Open Innovation (Territory: Worldwide excl. Asia-Pacific)

• IND-Enabling toxicology studies with a leading global CRO